AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Phase 1
Completed
- Conditions
- Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT05266404
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05267613
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Phase 3
Recruiting
- Conditions
- CarcinomaNon-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 324
- Registration Number
- NCT05261399
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines
Completed
- Conditions
- Covid-19
- Interventions
- Other: Pre-COVID-19Other: COVID-19Other: COVID-19 vaccination roll-out
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7641136
- Registration Number
- NCT05252442
- Locations
- 🇬🇧
Research site, Oxford, United Kingdom
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Phase 3
Completed
- Conditions
- Eosinophilic GastroenteritisEosinophilic Gastritis
- Interventions
- Biological: PlaceboBiological: Benralizumab
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT05251909
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT05250011
- Locations
- 🇮🇹
Research Site, Napoli, Italy
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 666
- Registration Number
- NCT05251259
- Locations
- 🇬🇧
Research Site, Watford, United Kingdom
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Phase 2
Completed
- Conditions
- HER2-mutant Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT05246514
- Locations
- 🇨🇳
Research Site, Zhengzhou City, China
OREIOS International Study
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1127
- Registration Number
- NCT05239507
- Locations
- 🇦🇪
Research Site, Abu Dhabi, United Arab Emirates
A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT05236543
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath